login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

US PYTHAGORAS data shows Aorfix is promising for patients with extremely tortuous anatomy


Tuesday, 12 Jun 2012 10:27
AorFix
AorFix


Lombard today announced the high angle clinical data results from the US PYTHAGORAS trial of its endovascular stent graft Aorfix. Data suggest that Aorfix has the potential to provide a less invasive treatment option for abdominal aortic aneurysm patients with highly angulated neck anatomy.


The unique data set, presented at the Society of Vascular Surgery (SVS) Annual Meeting (7–9 June, USA) by Mark Fillinger of Dartmouth Hitchcock Medical Centre, New Hampshire, USA, featured results from the world’s first and largest multicentre EVAR clinical trial studying patients with angles greater than 60 degrees.

Two hundred and five patients were recruited in the trial and the data resulted from 143 patients with highly-angulated aortic necks (angles between 60 and 110 degrees). Treatment of this patient group is not indicated in any stent grafts currently available in the USA.

The data presented showed that Aorfix performed well in extreme aortic neck angulations. Outcomes such as freedom from major adverse events (MAEs, as defined by the SVS) at 30 days and 365 days, were significantly lower than in patients undergoing open surgical repair (81.1% vs. 56.4%, p<0.0001 and 75.5% vs. 54.5%, p<0.0001 respectively). Although not tested in this trial, Fillinger noted that the outcomes were similar to EVAR trials of other stent grafts in much less severe anatomy.

The PYTHAGORAS trial’s results were achieved despite the inclusion of patients with predictors of worse short and long-term outcomes such as:

  • age (75.4+/-8 years vs. 69.2 +/-7 years, p=0.001);

  • proportion of female patients (35% vs. 20%, p=0.015);

  • congestive heart failure (14% vs. 4%, p=0.029); and

  • high neck angles (83+/-15 degrees, compared to SVS control group: 48+/-22 degrees, p<0.05)

“Aorfix has produced promising results in this extremely challenging patient group with high neck angles whose only treatment option currently is open surgical repair. Once available in the US, Aorfix should provide clinicians with a versatile option for treating patients with challenging abdominal aortic aneurysm anatomy, significantly expanding our ability to treat this condition in a minimally invasive fashion,”Fillinger said.

Simon Hubbert, chief executive of Lombard Medical said, “We are very pleased with the US PYTHAGORAS data, further evidence that Aorfix is an excellent treatment option for patients with extremely tortuous anatomy and who previously had no endovascular options. Our work supporting the US approval process for Aorfix is on track and we continue to anticipate US approval by the end of the year.”

Aorfix is currently commercially available in Europe and Lombard expects to launch the stent graft in the USA later this year, subject to FDA approval.




Add New Comment

Most popular


First implant completed in thoracoabdominal aortic aneurysm clinical study
Wednesday, 13 Jan 2016
The first US implant of the Gore Excluder thoracoabdominal branch endoprosthesis has taken place during a clinical study of the treatment of aortic aneurysms involving the visceral branch vessels. First implant completed in thoracoabdominal aortic aneurysm clinical study

Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy
Monday, 18 Jan 2016
The review, published in the January 2016 issue of the European Journal of Vascular and Endovascular Surgery (EJVES), further concludes that stroke/death rates after carotid stenting often exceed ... Systematic review of registry data suggests stroke or death rate after carotid stenting “significantly higher” than after endarterectomy

Medtronic launches OsteoCool radiofrequency ablation system in the US
Wednesday, 13 Jan 2016
The OsteoCool radiofrequency ablation system is designed to treat patients with painful spinal metastases. The system has been granted US Food and Drug Administration (FDA) 510(k) marketing clearance. Medtronic launches OsteoCool radiofrequency ablation system in the US

Features


Interventional radiology in trauma management
Friday, 05 Feb 2016
The role of interventional radiology in the management of severely traumatised patients began three to four decades ago with the embolization of the internal iliac arteries for massive pelvic ... Interventional radiology in trauma management

Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations
Monday, 30 Nov 2015
Miles Conrad, University of California San Francisco (UCSF), Interventional Radiology section and co-director of the UCSF HHT Centre of Excellence, spoke to Interventional News about a new device ... Microvascular plugs investigated in embolization of pulmonary arteriovenous malformations

Profiles


Gabriel Bartal
Thursday, 26 Nov 2015
“In the early days, I used to have to cut a 7F plastic tube, make side holes, send it off for ... Gabriel Bartal

Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions